Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
1/30/2021 - 5:45 - 6:45 PM
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™
  • MOC / ABIM MOC Part 2 Credit


Tuesday, August 4, 2020
4:00 – 5:00 PM ET (3:00 – 4:00 PM CST / 1:00 – 2:00 PM PST)

Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenges, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.

This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.


Welcome and Introduction
Understanding Optimal Evaluation of Patients with NASH
Staying Up-To-Date with the Latest NASH Advances
Q&A Session


The intended audiences for this educational initiative are hepatologists and gastroenterologists involved in the assessment and management of adults with NASH.


This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Implement guideline- and expert-recommended strategies to diagnose NASH and evaluate its severity
  • Evaluate the safety and efficacy data for the NASH therapies in late-stage development


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Rockpointe. The Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.


The Penn State College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through PSU’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.


Stephen A Harrison, MD
Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford Oxford, England
Medical Director
Pinnacle Clinical Research
San Antonio, TX
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF
Chairman, Department of Medicine
Inova Fairfax Medical Campus
Professor of Medicine
Virginia Commonwealth University
Inova Campus
Affiliate Professor of Biomedical Sciences
George Mason University
Falls Church, VA


Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Penn State College of Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclosures will be made known to participants prior to the activity.


To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


There is no fee for this activity. To receive credit, participants must register, view the live activity in its entirety, then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Jointly provided by Penn State College of Medicine and Rockpointe

  Physician CME


This program is supported by educational grant from Intercept Pharmaceuticals, Inc.


Breaking Down Long-Chain Fatty Acid Oxidation Disorder Treatment: Review of Current Care and the Latest Advances (Physicians)

Learn More

Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management

Learn More

Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy